Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 13/20 | 1.00 |
| ▸ | CDK8 | P49336 | 13/20 | 1.00 |
| ▸ | CDC7 | O00311 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16115995 | 0.84 | CCNC (0.72) | CCNCCDK8CDC7KDM4EMEN1 | |
| SCHEMBL30471697 | 0.81 | CCNC (0.69) | CCNCCDK8AURKAALDH1A1MAPT | |
| SCHEMBL16115264 | 0.80 | CCNC (0.71) | CCNCCDK8CDC7HTTKMT2A | |
| SCHEMBL16115168 | 0.80 | CCNC (0.71) | CCNCCDK8CDC7 | |
| SCHEMBL16115998 | 0.79 | CCNC (1.00) | CCNCCDK8CDC7ALDH1A1HTT | |
| SCHEMBL16115032 | 0.79 | CCNC (1.00) | CCNCCDK8CDC7ALDH1A1PIK3CB | |
| SCHEMBL20742135 | 0.79 | CCNC (0.65) | CCNCCDK8CDC7ALDH1A1CYP1A2 | |
| SCHEMBL16116044 | 0.78 | CCNC (0.68) | CCNCCDK8KDM4EMEN1AURKA | |
| SCHEMBL8853769 | 0.78 | CCNC (0.64) | CCNCCDK8CDC7KDM4EMEN1 | |
| SCHEMBL16116189 | 0.77 | CCNC (1.00) | CCNCCDK8CDC7ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014154723-A1 | NOVEL PYRROLE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | claimed |
| US-20090099237-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | claimed |
| WO-2009047163-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | claimed |
| CN-117396462-A | Antiviral compounds | 英菲克斯治疗有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2014154723-A1 | NOVEL PYRROLE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154723-A1 | NOVEL PYRROLE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| WO-2009047163-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| US-20090099237-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099237-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | CCNC 3527/4885CDK8 1687/4885CDC7 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.